EMMA

Emmaus Life Sciences, Inc. Common Stock

EMMA

Delisted

EMMA was delisted on the 10th of September, 2019.

Back to rankings

Healthcare Medical Care Facilities

Financial journalist opinion

Emmaus Life Sciences Reports Quarterly Financial Results

TORRANCE, Calif. , Aug. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2025.

Emmaus Life Sciences Reports Quarterly Financial Results

Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements

Changes Based on Additional Pharmacokinetics Data TORRANCE, Calif. , June 26, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it has received Food and Drug Administration (FDA) approval for changes to the labelling of Endari® to reflect additional prescribing information derived from post-marketing pharmacokinetic study data submitted by Emmaus.

Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements

Emmaus Life Sciences Reports Quarterly Financial Results

TORRANCE, Calif. , May 15, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. ( OTCQB : EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2025.

Emmaus Life Sciences Reports Quarterly Financial Results

Emmaus Life Sciences Reports Improved Quarterly Financial Results

TORRANCE, Calif. , Nov. 19, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. ( OTCQB : EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2024.

Emmaus Life Sciences Reports Improved Quarterly Financial Results

Emmaus Life Sciences Reports Quarterly Financial Results

TORRANCE, Calif. , Sept. 10, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC Markets: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year quarters ended March 31 and June 30, 2024.

Emmaus Life Sciences Reports Quarterly Financial Results

Emmaus Life Sciences Announces Willis C. Lee as Chief Executive Officer

TORRANCE, Calif. , July 23, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCMarkets: EMMA), a leader in sickle cell disease treatment, announced that Willis C.

Emmaus Life Sciences Announces Willis C. Lee as Chief Executive Officer

Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program

TORRANCE, Calif. , July 12, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced receiving the coveted "No Action Indicated" classification following a routine inspection by the United States Food and Drug Administration (FDA) of Emmaus' Postmarketing Adverse Drug Experience (PADE) compliance program.

Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program

Emmaus Life Sciences Reports 2023 Financial Results

TORRANCE, Calif. , July 3, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended December 31, 2023.

Emmaus Life Sciences Reports 2023 Financial Results

Emmaus Life Sciences Reports Delayed Filing of Annual Report

TORRANCE, Calif. , April 15, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported today that the filing of its Annual Report on Form 10-K for the year ended December 31, 2023 will be delayed.

Emmaus Life Sciences Reports Delayed Filing of Annual Report

Proactive Investors

Emmaus Life Sciences obtains marketing authorization for sickle cell disease teatment in Puerto Rico

Emmaus Life Sciences Inc (OTCQX:EMMA) said it had obtained marketing authorization from the Puerto Rico Department of Health for its sickle cell disease (SCD) treatment, Endari, an L-glutamine oral powder. This approval enhances accessibility to Endari for SCD patients in Puerto Rico, addressing challenges in accessing innovative treatments.

Emmaus Life Sciences obtains marketing authorization for sickle cell disease teatment in Puerto Rico

See News Rankings

Charts implemented using Lightweight Charts™